Obstetric Management of Adolescents with Bleeding Disorders

James, Andra H.

doi:10.1016/j.jpag.2010.08.004

Cited by 12 publications

(18 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Недостаточное увеличение массы тела (об-щая прибавка массы тела менее 7 кг) связано с рядом не-благоприятных исходов беременности, в том числе с низ-кой массой тела плода при рождении (22,2%), а также яв-ляется главным фактором риска смерти младенцев [18]. У подростков в возрасте 10-14 лет наиболее часто наблюда-ется патологическая прибавка массы тела во время бере-менности (13,0%) по сравнению с беременными в возрас-те 15-20 лет (10,6%) [18]. По результатам нашего исследо-вания, патологическая прибавка массы тела была выявле-на достоверно реже у пациенток 1-й группы (20%), чем у пациенток 2-й группы (33,8%), что противоречит приве-денным данным литературы.…”

Section: Discussionunclassified

Specific features of teenage pregnancy and delivery in relation to age

Михайлин¹,

Иванова²

2015

Ross. vestn. akush.-ginekol.

View full text Add to dashboard Cite

Section: Discussionunclassified

Specific features of teenage pregnancy and delivery in relation to age

Михайлин¹,

Иванова²

2015

Ross. vestn. akush.-ginekol.

View full text Add to dashboard Cite

“…6 These bleeding symptoms have implications for daily living and are associated with a reduced quality of life in VWD patients. 13,14 There are three types of VWD: type 1 and 3 are partial and complete quantitative deficiencies of VWF, respectively, while type 2 is comprised of four qualitative variants (type 2A, 2B, 2M and 2N). The prevalence based on patients who present to tertiary care centres with clinical symptoms is reported to be 0.01% 8,9 ; symptomatic VWD in primary care clinics is described to be at least 0.1% [8][9][10] ; and VWD can affect up to 1% of the general population based on epidemiological studies.…”

Section: Introductionmentioning

confidence: 99%

“…7 There is considerable variation in the published prevalence of VWD. 5,12,13 The subtype variations and the different clinical phenotypes contribute to the complexity of the diagnosis and management of VWD. 11,12 This prevalence is even higher among women with chronic heavy menstrual bleeding, ranging from 11% to 16% in different reports.…”

Section: Introductionmentioning

confidence: 99%

“…11,12 This prevalence is even higher among women with chronic heavy menstrual bleeding, ranging from 11% to 16% in different reports. 13,14 There are three types of VWD: type 1 and 3 are partial and complete quantitative deficiencies of VWF, respectively, while type 2 is comprised of four qualitative variants (type 2A, 2B, 2M and 2N). 5,12,13 The subtype variations and the different clinical phenotypes contribute to the complexity of the diagnosis and management of VWD.…”

Section: Introductionmentioning

confidence: 99%

“…13,14 There are three types of VWD: type 1 and 3 are partial and complete quantitative deficiencies of VWF, respectively, while type 2 is comprised of four qualitative variants (type 2A, 2B, 2M and 2N). 5,12,13 The subtype variations and the different clinical phenotypes contribute to the complexity of the diagnosis and management of VWD. 15 Additionally, there is a limited awareness of VWD, even within the healthcare community, leading to further challenges for patients and healthcare providers (HCPs) including delays in diagnosis and uncertainty about optimal management.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

An international survey to inform priorities for new guidelines on von Willebrand disease

et al. 2019

View full text Add to dashboard Cite

Introduction: von Willebrand disease (VWD) is an inherited bleeding disorder caused by a quantitative or qualitative dysfunction of von Willebrand factor. Clinicians, patients and other stakeholders have many questions about the diagnosis and management of the disease. Aim: To identify topics of highest importance to stakeholders that could be addressed by guidelines to be developed by the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF) and the World Federation of Hemophilia (WFH). Methods: A survey to determine and prioritize topics to be addressed in the collaborative development of guidelines for VWD was distributed to international stakeholders including patients, caregivers and healthcare providers (HCPs). Representatives of the four organizations coordinated the distribution strategy. The survey focused on both diagnosis and management of VWD, soliciting 7-point Likert-scale responses and open-ended comments, in English, French and Spanish. We conducted descriptive analysis with comparison of results by stakeholder type, gender and countries' income classification for the rating questions and qualitative conventional content data analysis for the open-ended responses.Results: A total of 601 participants responded to the survey (49% patients/caregivers and 51% healthcare providers). The highest priority topics identified were diagnostic criteria/classification, bleeding assessment tools and treatment options for women and surgical patients. In contrast, screening for anaemia and differentiating plasmaderived therapy versus recombinant therapies received lower ratings. Conclusion:This survey highlighted areas of importance to a diverse representation of stakeholders in the diagnosis and management of VWD, providing a framework for future guideline development and implementation. K E Y W O R D Sbleeding disorders, guidelines, multidisciplinary, patient engagement, stakeholders, survey, von Willebrand disease | 107 KALOT eT AL.

show abstract